Bolt Biotherapeutics, Inc. Operating Expenses
Bolt Biotherapeutics, Inc. (BOLT) reported Operating Expenses of $8.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $8.38M, a 23.92% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $7.63M, a 42.81% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $9.59M, a 43.34% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $9.87M, a 43.86% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating expenses for fiscal 2025 was $43.81M, a 45.74% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. operating expenses for fiscal 2024 was $80.74M, a 3.97% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. operating expenses for fiscal 2023 was $84.07M, a 12.47% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. operating expenses for fiscal 2022 was $96.05M, a 2.13% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.38M 10-Q · filed 2026-08-11 | $16.01M 10-Q · filed 2026-08-11 | $25.59M derived: sum of 3 quarters · filed 2026-08-11 | $35.46M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.63M 10-Q · filed 2026-05-12 | $17.21M derived: sum of 2 quarters · filed 2026-05-12 | $27.08M derived: sum of 3 quarters · filed 2026-05-12 | $38.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $9.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $19.46M derived: sum of 2 quarters · filed 2026-03-12 | $30.47M derived: sum of 3 quarters · filed 2026-08-11 | $43.81M 10-K · filed 2026-03-12 |
| 2025-09-30 | $9.87M 10-Q · filed 2025-11-12 | $20.89M derived: sum of 2 quarters · filed 2026-08-11 | $34.22M 10-Q · filed 2025-11-12 | $51.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $11.01M 10-Q · filed 2026-08-11 | $24.35M 10-Q · filed 2026-08-11 | $41.27M derived: sum of 3 quarters · filed 2026-08-11 | $58.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $13.34M 10-Q · filed 2026-05-12 | $30.25M derived: sum of 2 quarters · filed 2026-05-12 | $47.84M derived: sum of 3 quarters · filed 2026-05-12 | $71.71M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $16.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $34.50M derived: sum of 2 quarters · filed 2026-03-12 | $58.37M derived: sum of 3 quarters · filed 2026-03-12 | $80.74M 10-K · filed 2026-03-12 |
| 2024-09-30 | $17.58M 10-Q · filed 2025-11-12 | $41.46M derived: sum of 2 quarters · filed 2025-11-12 | $63.82M 10-Q · filed 2025-11-12 | $85.68M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $23.87M 10-Q · filed 2025-08-14 | $46.24M 10-Q · filed 2025-08-14 | $68.09M derived: sum of 3 quarters · filed 2025-08-14 | $88.80M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $22.37M 10-Q · filed 2025-05-12 | $44.22M derived: sum of 2 quarters · filed 2025-05-12 | $64.93M derived: sum of 3 quarters · filed 2025-05-12 | $86.20M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $21.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $42.57M derived: sum of 2 quarters · filed 2025-03-24 | $63.83M derived: sum of 3 quarters · filed 2025-03-24 | $84.07M 10-K · filed 2025-03-24 |
| 2023-09-30 | $20.71M 10-Q · filed 2024-11-12 | $41.98M derived: sum of 2 quarters · filed 2024-11-12 | $62.22M 10-Q · filed 2024-11-12 | $84.67M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $21.27M 10-Q · filed 2024-08-13 | $41.51M 10-Q · filed 2024-08-13 | $63.96M derived: sum of 3 quarters · filed 2024-08-13 | $88.42M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $20.24M 10-Q · filed 2024-05-14 | $42.69M derived: sum of 2 quarters · filed 2024-05-14 | $67.15M derived: sum of 3 quarters · filed 2024-05-14 | $91.60M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $22.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $46.91M derived: sum of 2 quarters · filed 2024-03-21 | $71.36M derived: sum of 3 quarters · filed 2024-03-21 | $96.05M 10-K · filed 2024-03-21 |
| 2022-09-30 | $24.46M 10-Q · filed 2023-11-09 | $48.91M derived: sum of 2 quarters · filed 2023-11-09 | $73.60M 10-Q · filed 2023-11-09 | $101.18M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $24.45M 10-Q · filed 2023-08-07 | $49.14M 10-Q · filed 2023-08-07 | $76.72M derived: sum of 3 quarters · filed 2023-08-07 | $101.00M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $24.69M 10-Q · filed 2023-05-11 | $52.27M derived: sum of 2 quarters · filed 2023-05-11 | $76.55M derived: sum of 3 quarters · filed 2023-05-11 | $100.31M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $27.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $51.86M derived: sum of 2 quarters · filed 2023-03-29 | $75.62M derived: sum of 3 quarters · filed 2023-03-29 | $94.05M 10-K · filed 2023-03-29 |
| 2021-09-30 | $24.28M 10-Q · filed 2022-11-10 | $48.04M derived: sum of 2 quarters · filed 2022-11-10 | $66.47M 10-Q · filed 2022-11-10 | $83.39M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $23.76M 10-Q · filed 2022-08-10 | $42.19M 10-Q · filed 2022-08-10 | $59.11M derived: sum of 3 quarters · filed 2022-08-10 | $71.51M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $18.43M 10-Q · filed 2022-05-12 | $35.35M derived: sum of 2 quarters · filed 2022-05-12 | $47.75M derived: sum of 3 quarters · filed 2022-05-12 | $58.93M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $16.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $29.33M derived: sum of 2 quarters · filed 2022-03-30 | $40.50M derived: sum of 3 quarters · filed 2022-03-30 | $49.41M 10-K · filed 2022-03-30 |
| 2020-09-30 | $12.40M 10-Q · filed 2021-11-09 | $23.58M derived: sum of 2 quarters · filed 2021-11-09 | $32.49M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $11.18M 10-Q · filed 2021-08-12 | $20.09M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $8.91M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |